Diovan generics approved in Japan for June launch
This article was originally published in Scrip
Japan's regulatory authorities have granted the latest batch approval to a group of generics that includes versions of Novartis's blockbuster antihypertensive Diovan (valsartan), which is now set to be opened up to its first such competition around the middle of the year.
You may also be interested in...
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.